BDP-9066

BDP-9066 is a potent and selective small molecule inhibitor of Myotonic dystrophy kinase-related CDC42-binding kinases (MRCK), specifically targeting the MRCKα and MRCKβ isoforms. Developed by the Beatson Institute for Cancer Research and the University of Glasgow, BDP-9066 functions by blocking the phosphorylation of myosin II light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1), which are critical regulators of actin-myosin contractility. By inhibiting these pathways, the compound suppresses the migration and invasion of various cancer cell types, including glioblastoma, breast cancer, and squamous cell carcinoma. Preclinical research has highlighted its potential in glioblastoma (GBM) to counteract radiation-induced cell invasion, a common cause of treatment resistance and recurrence.